24Feb 2023
MDS subclassification—do we still have to count blasts?

MDS subclassification—do we still have to count blasts?

The study proposed a classification of MDS based solely on genetic abnormalities, demonstrating that MDS can be separated into nine biologically distinct subgroups, which reflect biology better than blast counts. These genetically defined classes are associated with significant differences in overall survival. The poor survival of MDS subgroups with biallelic TP53 inactivation, complex karyotype, and RUNX1 mutations suggests that they should be further evaluated for joint treatment approaches with AML subgroups harboring the respective genetic abnormalities. The concept of classifying MDS based on biology using defining genetic abnormalities could help refine therapeutic strategies and future drug development in the era of precision medicine.

  • #oncology

Like

Save

Share